Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Feb;24(2):224-230.
doi: 10.1111/hiv.13357. Epub 2022 Aug 8.

Use of contraindicated antiretroviral drugs in people with HIV/HCV coinfections receiving HCV treatment with direct-acting antivirals-Results from the EuroSIDA study

Myroslava Nikolaichuk  1 , Amanda Mocroft  2   3 , Gilles Wandeler  4 , János Szlavik  5 , Magnus Gottfredsson  6   7 , Dag Henrik Reikvam  8 , Veronica Svedhem  9 , Hila Elinav  10 , Montserrat Laguno  11 , Kamal Mansinho  12 , Emma Devitt  13 , Nikoloz Chkhartishvili  14 , Georg Behrens  15 , Johannes Bogner  16 , Jean-Paul Viard  17 , Alan Winston  18 , Thomas Benfield  19 , Clifford Leen  20 , Olga Fursa  2 , Jürgen Rockstroh  21 , Lars Peters  2 ; EuroSIDA study group
Affiliations
Free article

Use of contraindicated antiretroviral drugs in people with HIV/HCV coinfections receiving HCV treatment with direct-acting antivirals-Results from the EuroSIDA study

Myroslava Nikolaichuk et al. HIV Med. 2023 Feb.
Free article

Abstract

Objectives: Our objective was to determine whether antiretroviral drugs (ARVs) were used according to the European AIDS Clinical Society (EACS) guidelines for people with HIV/hepatitis C virus (HCV) coinfection treated with direct-acting antivirals (DAAs) between 30 November 2014 and 31 December 2019 in the pan-European EuroSIDA study.

Methods: At each publication date of the EACS guidelines, plus 3 and 6 months, we calculated the number of people receiving DAAs with potential and actual ARV contraindications ('red shading' in the EACS guidelines). We used logistic regression to investigate factors associated with using contraindicated ARVs.

Results: Among 1406 people starting DAAs, the median age was 51 years, 75% were male, 57% reported injected drug use as an HIV risk, and 76% were from western Europe. Of 1624 treatment episodes, 609 (37.5%) occurred while the patient was receiving ARVs with potential contraindications; among them, 38 (6.2%; 95% confidence interval [CI] 4.3-8.2) involved a contraindicated ARV (18 non-nucleoside reverse transcriptase inhibitors), 16 involved protease inhibitors, and four involved integrase strand transfer inhibitors. The adjusted odds of receiving a contraindicated ARV were higher (3.25; 95% CI 1.40-7.57) among participants from east/central east Europe (vs. south) and lower (0.22; 95% CI 0.08-0.65) for 2015-2018 guidelines (vs. 2014). In total, 29 of the 32 (90.6%) patients receiving a contraindicated ARV and 441 of the 461 (95.7%) with potential ARV contraindications experienced a sustained virological response ≥12 weeks after stopping treatment (SVR12; p = 0.55).

Conclusion: In this large heterogenous European cohort, more than one-third of people with HIV/HCV coinfection received DAAs with potential ARV contraindications, but few received a contraindicated ARV. Use of contraindicated ARVs declined over time, corresponding to the increased availability of ARV therapy regimens without interactions with DAA across Europe. Participants who received a contraindicated DAA and ARV combination still had a high rate of SVR12.

Keywords: DAA; HCV; HIV; co-infection; contraindications.

PubMed Disclaimer

References

REFERENCES

    1. European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C. J Hepatol. 2018;69(2):461-511.
    1. European AIDS Clinical Society. EACS Guidelines. Version 11.0. October 2021. Accessed October 13, 2021. https://www.eacsociety.org/media/final2021eacsguidelinesv11.0_oct2021.pdf.
    1. Neant N, Solas C. Drug-drug interactions potential of direct-acting antivirals for the treatment of chronic hepatitis C virus infection. Int J Antimicrob Agents. 2020;56(1):105571.
    1. Smolders EJ, Smit C, de Kanter TMM, et al. Brief report: high need to switch cART or comedication with the initiation of DAAs in elderly HIV/HCV-coinfected patients. J Acquir Immune Defic Syndr. 2017;76(2):193-199.
    1. Maistat L, Kravchenko N, Reddy A. Hepatitis C in Eastern Europe and Central Asia: a survey of epidemiology, treatment access and civil society activity in eleven countries. Hepatol Med Policy. 2017;2:9.